GlassScriptPhysician profile
Dena J Howell
NPI 1013970284
$7,513.23
in general payments reported to CMS, 2019-2025
34 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $201 · 2021: $400 · 2022: $1,088 · 2023: $2,314 · 2024: $1,101 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,076 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,076.03 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,858.97 | 2019-2025 | |
| Janssen Biotech, INC. | $803.30 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $496.59 | 2019-2025 | |
| Incyte Corporation | $436.53 | 2021-2025 | Opzelura |
| Organogenesis INC. | $426.81 | 2023 | Puraply |
| Sun Pharmaceutical Industries INC. | $424.28 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $379.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $321.57 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $287.72 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $258.68 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Hill Dermaceuticals, INC. | $243.66 | 2022 | |
| Dermavant Sciences, INC. | $163.08 | 2022-2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $151.51 | 2019-2024 | Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.04 | 2019-2022 | |
| Ucb, INC. | $135.24 | 2019-2025 | Bimzelx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $134.24 | 2021-2025 | Adbry |
| Galderma Laboratories, L.P. | $129.54 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $101.14 | 2022-2024 | Sotyktu |
| Amgen INC. | $90.64 | 2019-2025 | Otezla |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.81 | 2023-2025 | Spevigo |
| Almirall LLC | $55.90 | 2019-2025 | Seysara |
| Mayne Pharma Commercial LLC | $54.50 | 2019-2020 | |
| Celgene Corporation | $40.80 | 2019 | |
| Organon LLC | $39.28 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $34.55 | 2019 | |
| Botanix Sb INC | $30.02 | 2025 | Sofdra |
| Dermira, INC. | $27.27 | 2019 | |
| Cipher Pharmaceuticals US LLC | $22.14 | 2025 | Spinosad, Natroba |
| Mallinckrodt Hospital Products INC. | $21.32 | 2025 | Acthar |
| Journey Medical Corporation | $18.76 | 2023 | |
| Fresenius Kabi USA, LLC | $15.46 | 2023 | Idacio |
| Taro Pharmaceuticals USA, INC. | $13.21 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $7.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dena Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.